Comparison of endoscopic healing and durability between infliximab originator and CT-P13 in pediatric patients with inflammatory bowel disease.

Authors:
Kim ES; Choi S; Choe BH; Park S; Lee YJ and 20 more

Journal:
Front Immunol

Publication Year: 2024

DOI:
10.3389/fimmu.2024.1284181

PMCID:
PMC10917915

PMID:
38455036

View on PubMed View on PMC View Publisher

Journal Information

Journal Title: Front Immunol

Detailed journal information not available.

Publication Details

Subject Category: Immunology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score

3/6

50.0% Transparent

Transparency Indicators

Click on green indicators to view evidence text

Core Indicators

Data Sharing

Code Sharing

COI Disclosure

Evidence found in paper:

"Conflict of interest For the past 3 years, BK has served as a speaker for Celltrion, Janssen, Abbvie, Takeda, Yuhan and Samsung Bioepis and has received research funding from Celltrion. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest."

Funding Disclosure

Evidence found in paper:

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (No. 2021R1A2C1011004)."

Protocol Registration

Open Access

Paper is freely available to read

Additional Indicators

Replication

Novelty Statement

Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025